Tenaya rises as FDA allows human trials for heart disease therapy

Tenaya Therapeutics

09/01/2023 15:07

** Shares of heart disease therapy developer Tenaya
Therapeutics Inc  TNYA.O  rise 6.6% to $2.09 in morning trade
    ** Co says the U.S. FDA has allowed co to begin human trials
of its experimental gene therapy, TN-201, to treat hypertrophic
cardiomyopathy (HCM)   
    ** HCM is a genetic disease caused by mutations in a gene
called MYBPC3 and is characterized by thickening of heart
muscles
    ** TN-201 is a gene therapy that uses a modified virus to
deliver a fully functional MYBPC3 gene to stop disease
progression - TNYA  
    ** TNYA plans to begin early-stage trial for the drug in Q3
this year and data from the trial is expected in 2024
    ** TNYA shares fell ~72.5% in the past 12 months
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))